IMMUCELL Business Summary

ImmuCell Corporation (ICCC) is a specialized animal health company that develops, manufactures, and markets scientifically proven products to improve the health and productivity of dairy and beef cattle. The company generates revenue primarily through the sale of its flagship First Defense product line, which provides "Immediate Immunity" to newborn calves against scours-causing pathogens like E. coli, coronavirus, and rotavirus. As of early 2026, ImmuCell has strategically pivoted its business model to focus exclusively on the high-growth scours segment, following a December 2025 FDA rejection of its Re-Tain mastitis treatment. This shift involves repurposing approximately $15.5 million in assets to expand First Defense production capacity and clear a multi-million dollar order backlog. ImmuCell competes directly with global animal health giants such as Zoetis Inc., Elanco Animal Health, Merck Animal Health, and Boehringer Ingelheim, positioning itself as a niche leader by offering non-antibiotic, colostrum-derived alternatives to traditional dam-level vaccines. Leadership is currently spearheaded by President and CEO Olivier te Boekhorst, who assumed the role in November 2025 after a distinguished 18-year tenure at IDEXX Laboratories and a recent stint as an Operating Partner at ARCHIMED. He is supported by CFO Timothy C. Fiori, also an IDEXX veteran with over two decades of financial and commercial experience in the livestock industry, and Bobbi Jo Brockmann, the Senior Vice President of Sales and Marketing. The company was founded in 1982 and has recently undergone a significant board transition, with long-time CEO Michael F. Brigham retiring from full-time work in early 2026 while remaining a director. Notable institutional investors include Renaissance Technologies, Geode Capital Management, and Cresset Asset Management, though the board is currently evaluating new compositions following the planned departures of directors Steven A. Rosgen and Bryan K. Gathagan at the 2026 Annual Meeting.